CEO of Dr Reddy's Laboratories, Erez Israeli believes his company's affordable medicines benefit the U.S. market and will be ...

Dr Reddy's Laboratories CEO expressed optimism about the Trump administration, projecting an edge due to ongoing U.S.-China ...

The company's North American revenue has seen a decline of over 9%. One of the primary worries is the reduction in revenues ...

Revlimid has arguably been the single biggest growth driver for Dr Reddy's in recent years, fueling record-high US sales last ...

Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in ...

Shares of Dr Reddy's Laboratories dropped 6% in early trade on Friday, a day after the company reported a third-quarter ...

Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1s (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...

Dr Reddy's Laboratories posted a 2% rise in net profit for Q3 2024, reaching Rs 1,413 crore, driven by strong market ...

Earlier in the day, the generic drugmaker reported consolidated net profit of Rs 1,414 crore ($163.7 million) for the quarter ...

Ladies and gentlemen, good day and welcome to the Quarter Three FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participant lines will be in the listen-only ...

Stay up-to-date with the Dr Reddys Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on a ...

Dr Reddy’s Labs & Dr Reddy’s Foundation announce launch of soil testing resource centre in Hyderabad: Our Bureau, Mumbai: Dr Reddys ...